Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Max-delbruck-centrum Fur Molekulare Medizin

Max-delbruck-centrum Fur Molekulare Medizin in Der Helmholtz-gemeinschaft

Max-delbrueck-centrum Fuer Molekulare Medizin

Erich Wanker

Hans Lehrach

David Bancroft

Annett Boeddrich

Niels Wedemeyer

Michael Schmidt

Gillian Bates

Elmar Maier

Franziska Schiele

Sebastian Meier-Ewert

Thomas Wiglenda

Julius Tachu Babila

Eberhard Scherzinger

Annett Boddrich

Sabine Engemann

Anne Ast

Alexander Buntru

Phoebe Markovic

Susanne Rautenberg

Dagmar Ehrnhöfer

Sandra Neuendorf

Martin Herbst

Jacqueline Walther

Klaus Genser

Gerlinde Grelle

Martin Strödicke

Albrecht Otto

Susanne Kostka

The present invention relates to a method for the quantification of seeding (Δt) of an amyloidogenic aggregate, methods for assessing the risk for development, predicting the onset or assessing the progression of a polyQ disease, and a method for identifying compounds that inhibit mHTT seeding activity (HSA) in vitro. Further, uses of fluorophore-bearing polyQ proteins, particularly mutant N-terminal huntingtin fragments comprising exon-1 and related soluble protein constructs are provided.

Fret-based method to measure seeding activity of misfolded protein species in biological samples

The present invention relates to compounds suitable for modulating huntingtin protein processing and useful for treating or preventing huntingtin-related disorders. The invention provides pharmaceutical compositions comprising said compounds and methods of syntheses thereof.

Enhancers of protein degradation

The present invention relates to compounds suitable as modulators of protein misfolding and/or protein aggregation. The compounds are particularly suitable as inhibitors of amyloid aggregate formation and/or modulators of amyloid surface properties, and/or as activators of degradation or reduction of amyloid aggregates.

Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates

The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases.

Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases

The present invention relates to methods of detecting the presence of detergent- or urea-insoluble amyloid-like fibrils or protein aggregates on filters. Preferably, said fibrils or aggregates are indicative of a disease, preferably of a neurodegenerative disease such as Alzheimer's disease or Huntington's disease. In addition, the present invention relates to inhibitors identified by the method of the invention, to pharmaceutical compositions comprising said inhibitors and to diagnostic compositions useful for the investigation of said amyloid-like fibrils or aggregates.

Method of detecting amyloid-like fibrils or protein aggregates

The present invention relates to novel compositions useful for elucidating the onset or progress of diseases such as Huntington's disease, that are associated with the formation of fibrils or protein aggregates. Further, the present invention relates to methods for monitoring formation of fibrils or protein aggregates as well as to methods for identifying inhibitors of fibril or protein aggregate formation. Additionally, the invention relates to inhibitors of the formation of fibrils or protein aggregates identified by the method of the invention as well as to pharmaceutical compositions that include the inhibitors.

Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation

The present invention relates to an improved method for the identification and optionally the characterisation of interacting molecules designed to detect positive clones from the rather large numbers of false positive clones isolated by conventional two-hybrid systems. The method of the invention relies on a novel combination of selection steps used to detect clones that express interacting molecules from false positive clones. The present invention provides for high-throughput interaction screens for the reliable identification of interacting molecules, which in turn can lead to the identification of substances inhibiting said interactions. Such inhibitors can find their use in the formulation of a pharmaceutical composition. The present invention further relates to kits useful for carrying out the method of the invention.

Method for the identification and characterization of interacting molecules by automated interaction mating

The present invention relates to an improved method for the identification and optionally the characterization of interacting molecules designed to detect positive clones from the rather large numbers of false positive clones isolated by two-hybrid systems. The method of the invention relies on a novel combination of selection steps used to detect clones that express interacting molecules from false positive clones. The present invention further relates to a kit useful for carrying out the method of the invention. The present invention provides for parallel, high-throughput or automated interaction screens for the reliable identification of interacting molecules.

Identification and characterization of interacting molecules

Growing community of inventors

Berlin, Germany

Erich Wanker